Concurrent estimation of lamivudine, tenofovir disoproxil fumarate, and efavirenz in blended mixture and triple combination tablet formulation by a new stability indicating RP-HPLC method

Abstract Background An easy, defined, rapid, and accurate reverse phase high-performance liquid chromatography method was developed and subsequently validated for the concurrent estimation of lamivudine, efavirenz, and tenofovir disoproxil fumarate in their pure blend and combined tablet formulation...

Full description

Saved in:
Bibliographic Details
Main Authors: Ramreddy Godela (Author), Vijayalaxmi Kammari (Author), Sowjanya Gummadi (Author), Durgaprasad Beda (Author)
Format: Book
Published: SpringerOpen, 2021-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_1ed32321eefa4a5eb823c9b93a5d6c08
042 |a dc 
100 1 0 |a Ramreddy Godela  |e author 
700 1 0 |a Vijayalaxmi Kammari  |e author 
700 1 0 |a Sowjanya Gummadi  |e author 
700 1 0 |a Durgaprasad Beda  |e author 
245 0 0 |a Concurrent estimation of lamivudine, tenofovir disoproxil fumarate, and efavirenz in blended mixture and triple combination tablet formulation by a new stability indicating RP-HPLC method 
260 |b SpringerOpen,   |c 2021-04-01T00:00:00Z. 
500 |a 10.1186/s43094-021-00249-9 
500 |a 2314-7253 
520 |a Abstract Background An easy, defined, rapid, and accurate reverse phase high-performance liquid chromatography method was developed and subsequently validated for the concurrent estimation of lamivudine, efavirenz, and tenofovir disoproxil fumarate in their pure blend and combined tablet formulation. An efficient and appropriate separation of the three analytes was attained with Zorbax eclipse XDB-Phenyl column, with a mobile phase of methanol: buffer (0.1% v/v formic acid in water) (73:27 v/v) at a flow rate of 1mL/min and isocratic elution by using 260nm as detection wavelength. Equal ratio of acetonitrile and water was used as diluent. Results The retention times of lamivudine, tenofovir disoproxil fumarate, and efavirenz were found at 2.6, 4.4, and 5.9 min respectively. The linear response for lamivudine, tenofovir disoproxil fumarate, and efavirenz was in the range of 15.0-45.0μg/mL, 15.0-45.0μg/mL, and 20.0-60.0 μg/mL respectively. The method validation was done in accordance to ICH guidelines and all validation parameters in compliance with ICH standards. The degradants produced by stress testing were well resolved from the peaks of active analytes, which stipulates the stability-indicating property of the method. Conclusion The method has the ability to separate lamivudine, efavirenz, and tenofovir disoproxil fumarate concurrently in blended powder and their combined tablet. All degradants produced by application of stress conditions were separated with high resolution and determined with good sensitivity that ensures the stability-indicating property of the method. Thus, the projected method has high probability to adopt in the pharmaceutical industrial sector. 
546 |a EN 
690 |a Lamivudine 
690 |a Efavirenz 
690 |a Tenofovir disoproxil fumarate 
690 |a Stress testing 
690 |a Stability indicating 
690 |a Isocratic elution 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Future Journal of Pharmaceutical Sciences, Vol 7, Iss 1, Pp 1-12 (2021) 
787 0 |n https://doi.org/10.1186/s43094-021-00249-9 
787 0 |n https://doaj.org/toc/2314-7253 
856 4 1 |u https://doaj.org/article/1ed32321eefa4a5eb823c9b93a5d6c08  |z Connect to this object online.